Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024141 (systemic lupus erythematosus)
 44,322 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We established chronic graft vs host disease in (BALB/c x A/J) F1 mice with the injection of lymphoid cells from the parental A/J strain. These animals developed glomerulonephritis, forefoot edema, alopecia, splenomegaly, and lymphadenopathy to various degrees, and all developed antinuclear antibodies. To determine whether these antibodies were directed against the small nuclear ribonucleoprotein (snRNP) particles that are characteristic targets for autoimmune responses in human rheumatic diseases, sera were studied in the 32P immunoprecipitation and immunoblotting assays. Among 20 mice, antibodies to snRNP developed in 10. These antibodies usually reached maximal levels about 4 wk after induction of graft vs host disease and generally fell thereafter. However, two mice developed antibodies to snRNP between the 10th and 20th wk of follow-up. Sera from six mice strongly recognized the U1 snRNP and an additional serum strongly bound both the U1 and U3 particles. Several sera contained lower levels of antibodies specific for the U3 and possibly pre-U2 snRNP particles. In immunoblots, sera that immunoprecipitated the U1 snRNP bound epitopes located on its 70,000 Da, A, B'/B, and/or C polypeptides. Sera that immunoprecipitated the U3 snRNP recognized a 34,000-Da polypeptide. These polypeptides are known to bear the autoantigenic epitopes that are recognized by human sera containing anti-U1 RNP and anti-U3 RNP autoantibodies. We conclude that chronic graft vs host disease in mice provides a model for the study of the autoimmune responses that characterize human diseases such as mixed connective tissue disease, scleroderma, and SLE.
 ...
PMID:Murine graft vs host disease. A model for study of mechanisms that generate autoantibodies to ribonucleoproteins. 337 98

To examine the role of small nuclear ribonucleoproteins (snRNPs) in mRNA splicing, we have injected SV40 DNA, in the presence or absence of anti-Sm or anti-(U1)RNP antibodies, into the nucleus of X. laevis oocytes, and analyzed the viral specific RNAs and proteins that were synthesized. In the absence of antibodies, the majority of the viral mRNAs were spliced, giving rise to transcripts and proteins analogous to those found in infected monkey cells. However, the relative efficiencies with which the various splice sites were utilized were different in the two cell types. When sera from systemic lupus erythematosus (SLE) patients containing anti-Sm or anti-(U1)RNP antibodies were coinjected with the viral DNA, splicing of L-strand-specific (late) mRNA was dramatically inhibited. Cleavage at both 5' and 3' splice sites was blocked, leading to an accumulation of unspliced primary transcripts. Neither the total amount of late RNA synthesized nor the formation of mature polyadenylated late mRNA 3' ends was affected. These results indicate that U1 snRNPs play a crucial role in mRNA splicing in vivo. Unexpectedly, the effects of the sera on E-strand-specific (early) viral mRNA splicing were different. All anti-Sm or -(U1)RNP sera tested had no detectable effect on the splicing of the mRNA coding for the small tumor antigen. A subset of these sera, however, inhibited large tumor antigen mRNA splicing. On the basis of these data it is suggested that different pre-mRNAs, or even different splice sites within the same pre-mRNA, have dissimilar interactions with snRNP particles in the splicing reaction.
 ...
PMID:Splicing pathways of SV40 mRNAs in X. laevis oocytes differ in their requirements for snRNPs. 608 49

Immunoprecipitation of human small nuclear ribonucleoproteins (snRNPs) containing the small nuclear RNAs U1, U2, U4, U5, and U6 with two antibodies produced in certain patients suffering from systemic lupus erythematosus was used to identify the polypeptides present on human U1 and U2 snRNPs. U1 and U2 snRNPs contain both common and unique polypeptides; visualization of the differences was possible through the use of non-methionine protein labeling and partial fractionation of snRNP populations. To facilitate comparisons with results from other laboratories, we have designated the snRNP polypeptides by their molecular weights. Four small polypeptides, P8, P9, P10, and P12, of 8,000 to 12,000 daltons, are each present in equal amounts on both U1 and U2 snRNPs. U1 snRNPs also contain a unique 30,000-dalton polypeptide, P30, whereas U2 snRNPs contain a unique 27,000-dalton, methionine-deficient polypeptide, P27. A closely migrating pair of polypeptides, P23 and P22, of 23,000 and 21,500 daltons, respectively, is present on both snRNPs; U2 snRNPs are enriched in the former, and U1 snRNPs are enriched in the latter.
 ...
PMID:Human U1 and U2 small nuclear ribonucleoproteins contain common and unique polypeptides. 618 8

We report here on the isolation and characterization of small nuclear ribonucleoproteins (snRNPs) and corresponding small nuclear RNA (snRNA) species from nuclei of Drosophila melanogaster. Velocity sedimentation in sucrose gradients was used to partially fractionate the RNPs; analysis of fractions so obtained suggests that, in general, one snRNP contains one snRNA. At least 11 species of snRNA are present in Drosophila nuclei; among them we identify a potential mammalian U1 homolog based on sequence homology. Autoimmune antiserum designated anti-Sm from patients with systemic lupus erythematosus recognizes nuclear antigens in Drosophila and precipitates seven species of snRNPs. The antigens in HeLa and Drosophila nuclei recognized by anti-Sm antibodies have been identified and compared. Anti-Sm antibodies at least bind to a 26,000-dalton polypeptide in HeLa extracts and to two polypeptides, one of 18,000 daltons and one of 26,000 daltons, in Drosophila extracts. This suggests that the 26,000-dalton polypeptide is an evolutionarily conserved antigenic component of Drosophila and HeLa snRNPs.
 ...
PMID:Small nuclear ribonucleoprotein complexes of Drosophila melanogaster. 618 15

The distribution of small nuclear ribonucleoprotein particles containing U snRNAs (U snRNPs) during oogenesis and early development in Xenopus was analyzed with a lupus antibody (anti-Sm) that reacts with snRNA-binding proteins. Fully grown oocytes and embryos prior to gastrulation were found to be relatively depleted of U snRNPs in their nuclei and to contain an excess of snRNA-binding proteins stored in the cytoplasm. During late blastula-early gastrula, or after microinjection of U snRNAs into the cytoplasm of a mature oocyte, the proteins migrate into the nucleus. Dot hybridization analysis showed that small previtellogenic oocytes already contain a maximal amount of U1 (and U2) snRNAs, which then decreases to about 20% of that value in fully mature oocytes, even though the cell's volume has increased enormously. Thus fully grown oocytes and eggs accumulate snRNA-binding proteins for use during early development, but this is not coupled with the accumulation of U snRNA.
 ...
PMID:Nucleocytoplasmic distribution of snRNPs and stockpiled snRNA-binding proteins during oogenesis and early development in Xenopus laevis. 618 95

Human small nuclear ribonucleoproteins (snRNPs) containing U1 and U2 snRNAs have been isolated from cultured cells by nonimmunological methods. The U1 snRNP population remained immunoprecipitable by systemic lupus erythematosis anti-RNP and anti-Sm antibodies throughout fractionation and contained polypeptides of molecular weights corresponding to those defined as U1 snRNP polypeptides by immunoprecipitation of crude extracts. The purified assemblies contained U1 RNA and nine snRNP polypeptides of molecular weights 67,000 (P67), 30,000 (P30), 23,000 (P23), 21,500 (P22), 17,500 (P18), 12,300 (P12), 10,200 (P10), 9,100 (P9), and 8,500 (P8). P67, P30, and P18 were unique to U1 snRNPs. The U2 snRNP population remained immunoprecipitable by the systemic lupus erythematosis anti-Sm antibody throughout fractionation. The purified U2 assemblies contained six polypeptides of molecular weights corresponding to those defined by immunoprecipitation to be common to U1 and U2 snRNPs including P23, P22, P12, P10, P9, and P8. In addition, U2 snRNPs contained a unique polypeptide of 27,000 Da.
 ...
PMID:Fractionation and characterization of human small nuclear ribonucleoproteins containing U1 and U2 RNAs. 618 35

Antibodies directed against small nuclear ribonucleoprotein ( snRNP ) particles are found in the Sm and RNP autoimmune sera from numerous patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD). These two reactivities differ in disease distribution as well as antigen specificity. Although sera from both of these autoimmune syndromes contain snRNP reactive antibodies, distinction in antigen binding specificity have been difficult to define because of the particulate nature of the snRNP antigen. To overcome this problem, while retaining the antigen in a native state, cells were pulse-labeled with [35S]methionine for 8 min to generate radioactive snRNP proteins in forms reflecting incomplete de novo particle assembly. Immunoprecipitation of snRNP antigen prepared in this manner revealed clearly distinct patterns of Sm and RNP immunorecognition . While Sm sera precipitated all eight labeled snRNP proteins, RNP antibodies precipitated only two of the eight. However, a brief pulse followed by periods of cold chase demonstrated that RNP sera can eventually coprecipitate all components of the complete particle. In addition to antibodies to the other six snRNP peptides, all Sm sera tested have been found to contain the RNP-like reactivity with snRNP proteins A and C. RNP reactivity with these two components is of particular interest because these proteins are unique in the metabolism of snRNPs. Defining and distinguishing the precise peptides recognized by Sm and RNP antibodies has helped to clarify the biochemical basis of the standard laboratory tests for these antigen reactivities.
 ...
PMID:Pulse labeling of small nuclear ribonucleoproteins in vivo reveals distinct patterns of antigen recognition by human autoimmune antibodies. 620 15

Small nuclear RNA molecules (snRNAs) are associated with polypeptides in vivo, forming small nuclear ribonucleoprotein complexes (snRNPs). These snRNP complexes are targets for certain autoimmune antisera. Antisera of the type anti-Sm precipitate (and therefore define) a class including U1, U2, U4, U5, and U6 snRNAs, whereas antisera of the anti-RNP type precipitate only U1 snRNPs. We used these two types of autoimmune antisera (from patients with systemic lupus erythematosus) to study the polypeptide components in human cells. Sequential immunoprecipitation of the complexes from nuclear extracts with anti-RNP and anti-Sm antibodies, along with radioimmunoassay of protein transfers, identified four polypeptides of 14,000 (P14), 17,000 (P17), 26,000 (P26), and 27,000 (P27) daltons that are present on all members of this class, whereas a 68,000-dalton (P68) polypeptide is present only on U1 snRNPs. Based on the radioimmunoassay, three of these polypeptides, P17, P26, and P27, are also the antigens for anti-Sm antisera, whereas P68 is the antigen for anti-RNP antisera. Long-term phosphate labeling experiments show that the only detectably phosphorylated polypeptide is P68, which contains phosphoserine.
 ...
PMID:Polypeptide components of human small nuclear ribonucleoproteins. 622 17

Cell-free translation of human poly(A)+ RNA was carried out to generate and analyze the protein constituents of small nuclear ribonucleoprotein (snRNP) particles. The snRNP proteins were identified by immunoprecipitation with sera from patients with systemic lupus erythematosus. Size fractionation of mRNA prior to translation revealed that these snBNP proteins are all encoded by separate messages. One of the proteins (the A protein, molecular weight 32,000) was seen to lose antigenicity upon RNase treatment either when extracted from cells or when generated in vitro. RNase treatment of immunoprecipitated snRNPs released the A protein in an electrophoretically pure form. Analysis of snRNPs translated in vitro revealed the presence of unassembled and assembled particles as determined by sucrose density gradient sedimentation. Post-translational assembly of snRNPs involving both RNA-protein binding (as revealed by A protein antigenicity) and associations of other snRNP proteins occurred in the in vitro system employed here. In addition, the presence of unassembled snRNP proteins permitted the determination of the precise antigen peptides recognized by Sm and RNP autoimmune sera. It was observed that Sm sera are capable of recognizing each of the eight snRNP proteins, whereas RNP sera recognize only two of the eight.
 ...
PMID:Synthesis and assembly of human small nuclear ribonucleoproteins generated by cell-free translation. 622 47

The size and structure of viral RNA species synthesized in nuclei isolated during the early phase of productive infection by adenovirus type 2 have been examined by electrophoresis in denaturing polyacrylamide cells and the nuclease S1 assay. The major products of transcription in vitro of early regions 1 and 2 in the adenoviral genome are processed RNA molecules that appear to be correctly spliced in isolated nuclei. Splicing of adenoviral RNA molecules is inhibited when nuclei are preincubated with antibodies from systemic lupus erythematosus patients that immunoprecipitate small nuclear ribonucleoprotein particles. The specificity of these antibodies suggests that ribonucleoprotein particles containing U1 RNA are required for splicing of the adenoviral RNA sequences we have examined.
 ...
PMID:A small nuclear ribonucleoprotein is required for splicing of adenoviral early RNA sequences. 694 Jan 64


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>